Objectives : The aim of this study was to determine the risk of major clinical and thromboembolic
events after cardioversion for atrial fibrillation in subjects treated with apixaban, an oral …

… Given apixaban is the most commonly used DOAC [… safety of apixaban with those of other
DOACs and vitamin K antagonists (VKA eg, warfarin). First, we sought to determine if apixaban …

… patients with atrial fibrillation in 39 countries. Patients were randomly assigned apixaban 5
mg … The primary safety outcome was major bleeding. We calculated CHADS 2 , CHA 2 DS 2 …

… The risk of stroke in patients with atrial fibrillation (AF) increases with age. In the ARISTOTLE
trial, apixaban when compared with warfarin reduced the rate of stroke, death, and bleeding…

… In this study of more than 90 000 patients with atrial fibrillation in the United States,
apixaban was associated with a lower rate of stroke or systemic embolism, as well as bleeding, …

… safety of uninterrupted apixaban during the periprocedural period of AF ablation. Therefore,
we should pay close attention to apixaban, particularly to its safety, … and safety of apixaban …

… efficacy and safety of apixaban versus warfarin were consistent in patients with and without
cancer. Our positive findings regarding apixaban use in patients with atrial fibrillation and …

The ARISTOTLE trial showed a risk reduction of stroke/systemic embolism (SE) and major
bleeding in non-valvular atrial fibrillation (NVAF) patients treated with apixaban compared to …

… evidence that apixaban is efficacious and safe across the … The superiority on efficacy and
safety outcomes of apixaban … major bleeding in patients with atrial fibrillation with low to normal …

… the effectiveness and safety of warfarin and the new oral anticoagulants (NOACs) apixaban,
… identified patients newly diagnosed with atrial fibrillation who initiated apixaban, dabigatran, …